MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Phase 1
Completed
Conditions
Graft Vs Host Disease
GVHD
Interventions
Drug: Pacritinib
Drug: Sirolimus
Drug: Tacrolimus
Procedure: Allogenic hematopoietic cell transplant (alloHCT)
First Posted Date
2016-09-07
Last Posted Date
2024-12-27
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
40
Registration Number
NCT02891603
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath